- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly unlikely to gain from Plavix patent loss, analyst says
May 17, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more
of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection
Thursday.
MoreCancer tools help Roche with Alzheimer's drug
May 13, 2012
Bloomberg NewsTreatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may
pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs
that attack the same protein as Roche’s experimental drug.
MoreRoche scraps hoped-for cholesterol blockbuster
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
MoreLilly: Forget Alzheimer's; think diabetes
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
MoreArrests made in $80M Lilly prescription drug heist
May 3, 2012
IBJ Staff and Associated Press, Bloomberg NewsAuthorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs
from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney's
office said Thursday.
MoreLilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
MoreLilly capitalizing on demand for testosterone drugs
May 2, 2012
Bloomberg NewsThe market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
MoreEli Lilly's Cialis faces faster-acting competition
April 30, 2012
IBJ Staff and Bloomberg NewsA Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and
Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
MoreLilly tops analyst expectations despite shrinking profit, revenue
April 25, 2012
J.K. WallLilly's quarterly sales and profit fell due to lost patent protection on Gemzar and Zyprexa. But sales of antidepressant Cymbalta,
blood thinner Effient, animal health products and sales in China grew by 20 percent or more.
MorePoison pills remain as Lilly shareholder vote falls short
April 16, 2012
J.K. WallThe proposal garnered support from the owners of 62 percent of Eli Lilly's outstanding shares. To pass, the proposal needed
approval from the owners of 80 percent of Lilly’s shares.
MoreLilly CEO says cost-cutting won’t solve sales losses
April 13, 2012
Bloomberg NewsEli Lilly and Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting
to overcome the revenue loss, CEO John Lechleiter said Thursday in Boston at the annual meeting of the Pharmaceutical Research
and Manufacturers of America.
MoreNew Lilly drug has small sales potential
April 9, 2012
J.K. WallEli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker
less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
MoreLilly wins FDA approval for Alzheimer's imaging agent
April 9, 2012
J.K. WallThe agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with
Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
MoreLilly receives Europe's OK for new Byetta use
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
MoreLilly to focus on cancer, diabetes in China, CEO says
March 20, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years,
focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
MorePROXY CORNER: Eli Lilly and Co.
March 17, 2012
Indianapolis-based Eli Lilly and Co discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
MoreLilly to try again to remove poison-pill provisions
March 6, 2012
J.K. WallEli Lilly and Co.'s board is once again recommending the removal of a provision that makes the company an almost impossible
target for hostile takeovers. The same proposal has fallen slightly short at each of the past two annual shareholder meetings.
MoreNew drugmaker code deprives docs of football, lunch for 2
March 1, 2012
Bloomberg NewsDoctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code
of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
MoreLilly plans 200 jobs at new $440M Ireland plant
February 27, 2012
IBJ Staff and Bloomberg NewsEli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork
in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
MoreDrugmakers singing same song: 2012 will be tough
February 2, 2012
Associated PressFor drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out
new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview
mirror any more.
MoreLilly eying deal with Turkish drug company
January 31, 2012
Bloomberg NewsEli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in
a deal that may value the Turkish drugmaker at $1 billion, sources say.
MoreLilly's quarterly profit tumbles, but tops Wall Street estimates
January 31, 2012
J.K. WallPatent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected
sales of other products.
MoreLilly's ex-partner wins FDA approval for diabetes drug
January 29, 2012
Bloomberg NewsAmylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly
and Co. co-developed the drug, but ended its partnership with Amylin last year.
MoreEli Lilly unit plans to buy feed-enzyme maker
January 24, 2012
Associated PressDrugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products
that improve poultry, egg and meat production.
MoreLechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Laura-the festivals and tastings are free. What does is strengthen the sense of community with activities. What are those empty lots doing for the Village? it's sad you can't see the good that this progress can do for the area. No one is requiring anyone to shop there. I guess you'd rather see a Dollar store move in or no, we'd rather see the property stand empty b/c change is out of the question.
Read down to the part about Brizzi. Someone needs to subpoena his "purchases" of Red RockPictures and Cellstar and his corresponding bank records, I mean c'mon, I'd like to see his alcohol usage records, too. http://diana-vice.blogspot.com/2011_01_01_archive.html
Wonder if my neighborhood can advertise our "retention" pond and act like it is a beach too?
a new record at the '11 salebration until they realized that it was a futile effort to get their crapwagon moter and crapwagon car up speed. And then they just quietly slunk off into the night and never spoke of it again. Nothing to see here folks.
millions for putting a company's bumper sticker on one of its Lolas. But you gotta take what you can get.